The U.S. Food and Drug Administration (FDA) has approved Rezdiffra, the first treatment specifically for adults suffering from noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis). This approval marks a significant milestone in the management of NASH, a severe form of fatty liver disease that leads to liver inflammation and damage without cirrhosis or excessive alcohol consumption.